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Abstract: Mitochondrial dysfunction is a relevant mechanism in cardiac aging. Here, we 
investigated the effects of late-life enalapril administration at a non-antihypertensive dose on 
mitochondrial genomic stability, oxidative damage, and mitochondrial quality control (MQC) 
signaling in the hearts of aged rats. The protein expression of selected mediators (i.e., 
mitochondrial antioxidant enzymes, energy metabolism, mitochondrial biogenesis, dynamics, and 
autophagy) was measured in old rats randomly assigned to receive enalapril (n = 8) or placebo (n = 8) 
from 24 to 27 months of age. We also assessed mitochondrial DNA (mtDNA) content, citrate 
synthase activity, oxidative lesions to protein and mtDNA (i.e., carbonyls and the abundance of 
mtDNA4834 deletion), and the mitochondrial transcription factor A (TFAM) binding to specific 
mtDNA regions. Enalapril attenuated cardiac hypertrophy and oxidative stress-derived damage 
(mtDNA oxidation, mtDNA4834 deletion, and protein carbonylation), while increasing 
mitochondrial antioxidant defenses. The binding of mitochondrial transcription factor A to 
mtDNA regions involved in replication and deletion generation was enhanced following enalapril 
administration. Increased mitochondrial mass as well as mitochondriogenesis and autophagy 
signaling were found in enalapril-treated rats. Late-life enalapril administration mitigates 
age-dependent cardiac hypertrophy and oxidative damage, while increasing mitochondrial mass 
and modulating MQC signaling. Further analyses are needed to conclusively establish whether 
enalapril may offer cardioprotection during aging. 
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1. Introduction 
The intimate mechanisms that underlie cardiac aging are yet to be fully deciphered. Yet, wide 
consensus exists on the central role played by mitochondrial dysfunction [1]. Besides their function 
in cellular energy provision, these organelles also serve as the hub for many other activities, 
including metabolic signaling, regulation of programmed cell death, calcium and iron buffering, and 
iron-sulfur cluster and heme biosynthesis [2]. As such, the maintenance of well-performing 
mitochondria is instrumental to cell viability. Like neurons and skeletal myocytes, cardiomyocytes 
are post-mitotic cells with very limited regenerative capacity and are thus devoid of a replicative 
dilution of damage [3]. Therefore, repair and recycling processes are essential for mitochondrial 
quality control (MQC), which is accomplished through an integrated network of pathways 
operating sequentially from individual molecules to the whole organelle [4]. 
During aging, the generation of reactive oxygen species (ROS) increases in cardiomyocyte 
mitochondria [5]. The concomitant decrease in the efficiency of antioxidant defenses contributes to 
establishing an oxidant environment [5,6], which is thought to play a key role in mitochondrial 
dysfunction during cardiac aging [7]. Indeed, mitochondrial macromolecules, including 
mitochondrial DNA (mtDNA), are immediate targets of ROS. As a result of persistent oxidative 
stress, both quantitative and qualitative mtDNA alterations may occur [8], which impact mtDNA 
structure and function. Noticeably, the frequency of the common 4977-bp mtDNA deletion, a typical 
oxidative stress-derived lesion [9], increases with age in the human heart and is 5- to 15-fold higher 
in people over 40 years of age compared with younger adults [10,11]. 
Oxidation of DNA bases is another extensively investigated mutation associated with aging 
[12]. Of the four DNA bases, guanine has the lowest reduction potential and is the most susceptible 
to oxidation [13]. Oxidized guanine accumulates in the aging heart, especially in the GC-rich 
mtDNA [14], and can induce transversion mutations [15]. Furthermore, a direct relationship 
between base oxidation and the generation of mtDNA deletions has been proposed [16], such that 
oxidized bases trigger the recombination of mtDNA segments in the presence of direct repeats 
flanking the deletion regions by facilitating DNA strand separation [16]. 
The mitochondrial transcription factor A (TFAM), a nuclear-encoded histone-like protein that 
was originally attributed a role in mtDNA replication and transcription [17], may also be involved in 
the sensing and repair of mtDNA oxidative damage [18]. The mechanism whereby TFAM intervenes 
in mtDNA repair is presently unknown. However, TFAM seems to preferentially bind to mtDNA 
damage hot spots [19]. This finding leads to the hypothesis that TFAM binding might hinder 
mtDNA repair by limiting the access of repairing enzymes to the site of lesions and/or by trapping 
the accessed enzymes and preventing their activities [19]. 
Previous findings from our group support a mitochondrial protective effect of 
angiotensin-converting enzyme (ACE) inhibitors in the skeletal muscle of old rats [20,21]. 
Furthermore, Piotrkowski et al. [22] showed that enalapril given at a non-antihypertensive dose 
prevented cardiac hypertrophy and ameliorated cardiomyocyte mitochondrial dysfunction in 
spontaneously hypertensive rats. Whether ACE inhibition affects oxidative stress, mtDNA homeostasis, 
and MQC in the aging heart and thus offers cardioprotection during aging is currently unknown. 
The present study was therefore undertaken to investigate the effects of enalapril 
administration started late in life on mitochondrial genomic stability, oxidative damage, and MQC 
signaling in the rat heart. In particular, we tested the hypothesis that enalapril administration at a 
non-antihypertensive dose would attenuate oxidative stress and some of its consequences (i.e., 
mtDNA damage, mtDNA4834 deletion, and protein carbonylation), increase mitochondrial mass, 
promote mitochondrial fusion, and stimulate autophagy. 
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2. Materials and Methods 
2.1. Animals 
Fischer 344×Brown Norway F1 hybrid rats were purchased from the National Institute on 
Aging Colony at Harlan Industries (Indianapolis, IN, USA). Rats were received at 22 months of age 
and housed individually on a 12-h light/dark cycle in a specific pathogen-free facility accredited by 
the American Association for Accreditation of Laboratory Animal Care. Health status, body weight 
(BW), and food intake were monitored daily. Rats were randomly assigned to receive 20 mg kg−1 
day−1 enalapril (n = 8) or placebo (n = 8) from 24 to 27 months of age. The enalapril dose did not 
modify blood pressure according to pilot experiments conducted in our laboratory [23]. Drug 
delivery was accomplished by compounding treatments into bacon-flavored food tablets (Bio-Serv, 
Frenchtown, NJ, USA). Placebo-containing food tablets were identical to those delivering enalapril, 
except for drug omission. Drug- and placebo-containing tablets were administered separately from 
the standard chow. Drug doses were tailored daily according to the animal’s weight. All rats 
consumed the whole treatment tablet at each meal. Animals were anesthetized before being 
sacrificed, weighed, and the heart was immediately removed, weighed, snap-frozen in isopentane 
cooled by liquid nitrogen, and stored at −80 °C until analysis. The study and experimental protocols 
were approved by the University of Florida’s Institutional Animal Care and Use Committee 
(protocol number 200801599) and complied with the International Guiding Principles for Biomedical 
Research Involving Animals. 
2.2. Western Immunoblotting 
Western blot experiments were carried out on heart homogenates from each animal of the two 
experimental groups. Ten μg of total proteins were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently electroblotted onto 
polyvinylidenefluoride (PVDF) hybond-P membranes (GE Healthcare, Buckinghamshire, UK), 
using the Criterion Blotter (Bio-Rad Laboratories, Hercules, CA, USA). After the protein transfer, 
membranes were probed overnight at 4 °C with primary antibodies targeting the following proteins: 
protein kinase B (AKT), phospho-AKT (P-AKT), 5′ AMP-activated protein kinase (AMPK), 
phospho-AMPK (P-AMPK), Beclin 1, dynamin-related protein 1 (Drp1), Forkhead boX O3a 
(FoXO3a), phospho-FoXO (P-FoXO3a), mitofusin 2 (Mfn2), manganese superoxide dismutase 
(MnSOD), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), 
peroxiredoxin III (PrxIII), oxidized PrxIII (Prx-SO3), sequestosome 1 (SQSTM1) p62 protein, TFAM, 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, loading control). Technical specifications 
of the primary antibodies used are listed in Table 1. The following day, membranes were incubated 
for 1 h at room temperature with appropriate peroxidase-conjugated secondary antibodies (Santa 
Cruz Biotechnology, Santa Cruz, CA). Blots were visualized using the ECL Plus Western Blotting 
Detection Reagents and ECL films (GE Healthcare). Autoradiographs were acquired by the 
ChemiDoc MP Imaging System and analyzed by Quantity One software (Bio-Rad Laboratories). The 
densitometric value of optical density (OD) units of each protein band immunodetected was then 
related to the corresponding GAPDH signal intensity (loading control) and normalized by 
comparison with the placebo group. 
Table 1. Technical specifications of the primary antibodies used for Western immunoblotting. 
Antibody Manufacturer and Catalogue Number Type Species Dilution Detected Band MW (kDa) 
Anti AKT 
Cell Signaling 
(Berverly, MA, USA) Polyclonal Rabbit 1:20,000 60 
(sc-9272) 
Anti AMPK 
Cell Signaling 
Polyclonal Rabbit 1:5000 62 
(sc-2532) 
Anti Beclin 1 
Millipore 
(Burlington, MA, USA) Polyclonal Rabbit 1:300,000 52 
(AB15417) 
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Anti Drp1 
Abnova 
(Taiwan, China) Monoclonal Mouse 1:10,000 80 
(H00010059-M01) 
Anti FoxO3a 
Cell Signaling 
Polyclonal Rabbit 1:10,000 97 
(sc-9467) 
Anti MFN2 
Abnova 
(Taiwan, China) Monoclonal Mouse 1:10,000 80 
(H00009927-M03) 
Anti MnSOD 
Assay Designs 
(Farmingdale, NY, USA) Polyclonal Rabbit 1:40,000 26 
(SOD-110) 
Anti P-AKT 
Cell Signaling 
Polyclonal Rabbit 1:5000 60 
(sc-9271) 
Anti 
P-AMPK 
Cell Signaling 
Polyclonal Rabbit 1:5000 62 
(sc-2531) 
Anti 
P-FoxO3a 
Cell Signaling 
Polyclonal Rabbit 1:5000 97 
(sc-9465) 
Anti PGC-1α 
Santa Cruz Biotechnology 
(Dallas, TX, USA) Polyclonal Goat 1:10,000 91 
(sc-5816) 
Anti PrxIII 
Ab Frontier 
(Seoul, South Korea) Polyclonal Rabbit 1:160,000 26 
(LF-PA0030) 
Anti Prx-SO3 
Ab Frontier 
(Seoul, South Korea) Polyclonal Rabbit 1:30,000 26 
(LF-PA0004) 
Anti 
SQSTM1/p62 
Sigma-Aldrich 
(St. Louis, MO, USA) Monoclonal Rabbit 1:20,000 62 
(P0066) 
Anti TFAM 
Santa Cruz Biotechnology 
(Dallas, TX, USA) Polyclonal Goat 1:30,000 25 
(sc-19050) 
Anti GAPDH 
Cell Signaling 
Monoclonal Rabbit 1:100,000 37 
(sc-2118) 
AKT, protein kinase B; AMPK, AMP-activated protein kinase; Drp1, dynamin-related protein 1; 
FoXO3a, Forkhead boX O3a; GADPH, glyceraldehyde 3-phosphate dehydrogenase; Mfn2, mitofusin 
2; MnSOD, manganese superoxide dismutase; MW, molecular weight; P-AKT, phosphorylated AKT; 
P-AMPK, phospho-AMPK; P-FoXO3a, phosphorylated FoXO3a; PGC-1α, eroxisome 
proliferator-activated receptor gamma coactivator 1-alpha; PrxIII, peroxiredoxin III; Prx-SO3, 
oxidized PrxIII; SQSTM1/p62, sequestosome 1 p62; TFAM, mitochondrial transcription factor A. 
2.3. Quantification of Mitochondrial DNA Content 
Genomic DNA was isolated from the heart of each animal from the two experimental groups 
and checked for quality as reported previously [24]. Thirty-40 mg of heart tissue were used. Total 
DNA was quantified using a NanoDrop 2000/2000c spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA, USA) and integrity was verified by gel electrophoresis on 0.8% agarose gel in 1× TBE 
(90 mM Tris-borate pH 7.4, 90 mM boric acid, 2.5 mM EDTA). Mitochondrial DNA content was 
measured using a quantitative real-time polymerase chain reaction (qRT-PCR), as described 
elsewhere [25]. Quantitative RT-PCR amplification reactions were carried out on an ABI PRISM 7300 
Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using SYBR Green 
chemistry (Power SYBR Green Master Mix, Thermo Fisher Scientific). Primers for the rat 
mitochondrial D-loop region and for the rat nuclear β-actin gene were designed with the Primer 
Express 3.0 software (Applied Biosystems) (Table 2). The method was validated by primer-limiting 
experiments (200 nM for each primer pair concentrations) and by evaluating the equal reaction 
efficiency of the two amplicons. A melting curve analysis and gel electrophoresis were used to 
control the amplification specificity. Each sample was analyzed in triplicate in 25 μL final volume. 
The reaction mixture consisted of iTaq SYBR Green Supermix PCR 1× Master Mix (Bio-Rad 
Laboratories), 0.2 μM forward and reverse primers, and DNA template (25 ng). The amplification 
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proceeded for 40 cycles. The quantification of the relative mtDNA content was performed according 
to the Pfaffl mathematical model [26]. In particular, the difference in threshold cycle values (ΔCt, 
namely Ct D-loop - Ct β-actin) was used as a measure of the relative abundance of the mitochondrial 
genome. To compare mtDNA quantity between experimental groups, the relative amount of 
mtDNA to nuclear DNA was calculated using the following equation: R = 2ΔΔCt, where R is the 
calculated ratio and ΔΔCt is the ΔCt analyzed class-ΔCt reference class value, with the placebo 
group taken as the reference.  
Table 2. Oligonucleotide primer sequences. 
Primer Set Forward Primer Reverse Primer (nps) (nps) 
β-actin 5′CCCAGCCATGTACGTAGCCA3′ 5′CGTCTCCGGAGTCCATCAC3′ 2181–2200 2266–2248 
D-loop 5′CACCCCCTACACCTGAAACTT3′ 5′TTTGTGTCGGGAAATTTTACCAAT3′ 16,092–16,112 16,250–16,227 
mtDNA 5′GGTTCTTACTTCAGGGCCATCA3′ 5′TGATTAGACCCGTTACCATCGA3′ 15,785–15,806 15,868–15,847 
mtDNA4834 5′AAGGACGAACCTGAGCCCTAATA3′ 5′CGAAGTAGATGATGCGTATACTGTA3′ 8109–8131 13,020–12,996 
ND1 5′AACGCCCTAACATCAATTGTATTCC3′ 5′TGGTCATATCGAAAACGGGGG3′ 3442–3466 3590–3570 
OriL 5′CAGCTAAATACCCTACTTACTGG3′ 5′GCCCCCTTTTTACCAAAAAGCC3′ 5120–5142 5270–5249 
Nucleotide numbering is reported according to the GenBank accession number AY172581 (Rattus 
norvegicus, complete mitochondrial genome), except for the β-actin primer set which is reported 
according to GenBank accession number V01217.1 (Rattus norvegicus, β-actin gene). nps: nucleotide 
positions, mtDNA: mitochondrial DNA. 
2.4. Relative Quantification of Mitochondrial DNA4834 Deletion 
The level of the mtDNA4834 deletion was measured by qRT-PCR via SYBR Green chemistry on 
an ABI PRISM 7300 Sequence Detection System (Applied Biosystems) as previously reported [25]. 
Primers were designed with the Primer Express 3.0 software (Applied Biosystems) for the rat 
mtDNA 4.8-kb deleted region and for the rat mtDNA D-loop region, generally undeleted (Table 2). 
The method was validated by primer-limiting experiments and by evaluating the equal reaction 
efficiency of the two amplicons. Amplification specificity was controlled by a melting curve analysis 
and following gel electrophoresis. Each sample was analyzed in triplicate in 25 μL final volume and 
fluorescence spectra were monitored. The reaction mixture consisted of iTaq SYBR Green Supermix 
PCR 1× Master Mix (Bio-Rad Laboratories), 0.2 μM forward and reverse primers, and DNA template 
(2.5 μL of diluted 1:10). After 10 min of denaturation at 95 °C, amplification proceeded for 40 cycles, 
each consisting of denaturation at 95 °C for 15 s, annealing, and extension at 60 °C for 1 min. The 
relative abundance of the 4.8-kb deleted mtDNA in placebo and enalapril-treated rats, all 
normalized to the corresponding total mtDNA, was calculated according to the Pfaffl mathematical 
model [26] using the equation R = 2ΔΔCt, as described above. 
2.5. Measurement of Citrate Synthase Activity 
Total proteins were purified from 15 mg of frozen heart samples by homogenization in a buffer 
containing 100 mM mannitol, 1 mM ATP, 0.2% bovine serum albumin (BSA), 100 mM KCl, 3 mM 
MgCl2, 5 mM Tris-buffer, 1 mM EDTA, pH 7.4. Protein concentration was determined by the Bradford 
method [27] according to the supplier’s instructions (Bio-Rad Laboratories). Citrate synthase (CS) activity 
(μmol × min–1 × g tissue–1) was determined in tissue homogenates according to the method developed 
by Srere [28]. Briefly, 100 μg of total proteins were incubated in 1 mL of assay buffer containing 0.31 
mM acetyl-CoA, 100 mM Tris buffer (pH 8.1), 0.25% Triton X-100, 0.1 mM 5,5′-dithio-bis-2-nitrobenzoic 
acid, and 0.5 mM oxaloacetate at 30 °C. Citrate synthase activity was determined 
spectrophotometrically by measuring the rate of production of thionitrobenzoic acid at 412 nm. 
2.6. Detection of Mitochondrial DNA Oxidative Damage 
To detect oxidative base modifications in mtDNA, we adapted the PCR assay developed by 
Pastukh et al. [29], as previously described [19]. Analyses focused on short sequences of specific 
mtDNA genes: A portion of the cytochrome b gene (complex III of the electron transport chain); the 
OriL origin together with a portion of the CO I gene; a portion of the D-loop with the OriH origin of 
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replication; and a sequence including the direct repeat 1 of the 4.8-kb deletion. Primers used to 
amplify the sequences of interest are listed in Table 2. The basis of the assay is the treatment of DNA 
with the enzyme formamidopyrimidine [fapy]-DNA glycosylase (Fpg) (New England Biolabs, 
Beverly, MA, USA) which results in strand cleavage at sites of oxidized purines, thereby creating 
single-strand breaks that block PCR amplification. Differences in PCR amplification between 
Fpg-treated and untreated DNA are thus a specific indicator of the presence of oxidative base 
damage. The Fpg cleavage reaction was performed by incubating 250 ng of DNA with 8 U of Fpg in 
1× NEBuffer 1 (10 mM Bis/Tris propane-HCl, 10 mM MgCl2, 1 mM DTT, pH 7.0) and 100 μg/mL BSA 
in a volume of 50 μL. Incubations were carried out at 37 °C for 1 h. [fapy]-DNA glycosylase was then 
inactivated by heating at 60 °C for 5 min. An aliquot of 10 ng of DNA was used for the PCR assay to 
detect Fpg-sensitive cleavage sites. Data are presented as the fraction of intact DNA, calculated as 
the ratio of band intensities of Fpg-treated and untreated samples [30]. 
2.7. Analysis of TFAM Binding to mtDNA by Mitochondrial Immunoprecipitation 
The binding of TFAM to specific regions of mtDNA was analyzed using mtDNA 
immunoprecipitation (mIP). The measurement of the relative amounts of mtDNA 
immunoprecipitated by TFAM was carried out by qRT-PCR as previously described [25]. Three 
primer pairs, listed in Table 2, were designed to include, respectively, a part of the D-loop with the 
OriH origin of replication; the Ori-L origin together with a portion of the CO I gene; and a part of the 
ATPase 6 gene containing the direct repeat 1 of the 4.8-kb deletion. Input and mIP mtDNAs were 
subjected to qRT-PCR amplification reactions via SYBR Green chemistry on an ABI PRISM 7000 
Sequence Detection System (Applied Biosystems). The reaction mixture consisted of iTaq SYBR 
Green Supermix PCR 1× Master Mix (Bio-Rad Laboratories), 0.2 μM forward and reverse primers, 
and 2.5 μL of the input or immunoprecipitated DNA aliquots with or without anti-TFAM antibodies 
(diluted 1:10). After a 10-min denaturation at 95 °C, samples were amplified for 40 cycles, each 
consisting of denaturation at 95 °C for 15 s, annealing, and extension at 60 °C for 1 min. The 
calculation of the amount of TFAM-bound mtDNA was performed according to the formula 
2ΔCTx-2ΔCTb, where ΔCTx is the difference between the CT values of the input and the 
immunoprecipitated sample and ΔCTb is the CT difference between the CT values of the input and 
the no-antibody sample [31]. 
2.8. Determination of Protein Carbonylation 
The levels of protein-bound carbonyls were evaluated by means of the OxyBlot Protein 
Oxidation Detection Kit (Millipore, Billerica, MA, USA) according to the manufacturer’s 
instructions. Equal amounts of total proteins (10 μg) were treated with 6% SDS in 10 μL final 
volume. Carbonyl groups in the protein side chains were derivatized with 2,4-dinitrophenyl 
hydrazine (DNPH) to form 2,4-dinitrophenyl hydrazone (DNP hydrazone) following an incubation 
of 15 min at room temperature. Negative controls were obtained by incubating protein extracts with 
a derivatization control solution at the same incubating conditions. After blocking the derivatization 
reaction with a neutralization solution, β-mercaptoethanol was added at a final concentration of 0.74 M. 
Protein samples were separated on a 4 to 15% Criterion TGX Stain-Free Precast Gels (Bio-Rad 
Laboratories) and processed by Western immunoblotting. Blotted membranes were blocked in 1% 
BSA in PBS 1×, 0.05% Tween 20 and incubated overnight at 4 °C with a specific antibody against 
DNP hydrazone (1:300 in 1% BSA in 1× PBS, 0.05% Tween 20) and for 1 h at room temperature with 
the secondary antibody (1:150 in 1% BSA in 1× PBS, 0.05% Tween 20). The normalization of protein 
samples was performed with the fluorescent detection in Stain Free Blot using a ChemiDoc MP 
imaging system (Bio-Rad Laboratories) on the PVDF membrane. The quantification of carbonylated 
proteins was performed on Image Lab 6.0 software (Bio-Rad Laboratories) using the “Total Lane 
Protein” setting.  
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2.9. Statistical Analysis 
The normal distribution of data was ascertained through the Kolmogorov–Smirnov test. 
Subsequently, comparisons between experimental groups (i.e., placebo- and enalapril-treated rats) 
were performed by t-test statistics. Changes in food intake over time in the two treatment groups 
were analyzed by two-way analysis of variance for repeated measures. All analyses were performed 
using the GraphPrism 5.03 software (GraphPad Software, Inc., San Diego, CA, USA), with the 
statistical significance set at p < 0.05. 
3. Results 
3.1. Morphological and Physiological Characteristics of Experimental Animals 
Body weight was comparable between treatment groups both at baseline and at the time of 
sacrifice (Table 3). In contrast, the heart weight, either absolute or adjusted by BW, was significantly 
lower in enalapril-treated rats compared with controls (p = 0.0359 for both). Food consumption was 
slightly lower in rats receiving enalapril and declined to a similar extent in both groups over time. 
Table 3. Morphological characteristics of experimental animals at the time of sacrifice. 
 Placebo (n = 8) Enalapril (n = 8) p-Value 
Body weight, g 577.3 ± 12.9 551.0 ± 16.3 0.2228 
Heart weight (absolute), g 1.53 ± 0.03  1.37 ± 0.05 0.0359 
Heart weight by body weight 2.92 ± 0.06 2.63 ± 0.10 0.0359 
Data are shown as mean ± standard error of the mean. 
3.2. Oxidative Stress and Mitochondrial DNA Lesions 
One relevant outcome of mitochondrial dysfunction is oxidative stress. Therefore, we estimated 
the oxidative burden of our samples by determining the protein expression of two mitochondrial 
ROS-scavenging enzymes and the level of protein-bound carbonyls in the heart of the two rat groups. 
The content of mitochondrial PrxIII was increased in rats treated with enalapril (p = 0.0140; 
Figure 1A). Despite an overall reduced level of protein-bound carbonyls in the heart of 
enalapril-treated rats (p = 0.0457; Figure 2), an accumulation of the oxidized sulphonic form of Prx III 
(Prx-SO3) was identified in the same experimental group (p = 0.0029; Figure 1B). In contrast, the 
expression of MnSOD was higher in enalapril-treated rats compared with the placebo group (p = 0.0450; 
Figure 1C). 
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Figure 1. Protein expression of the mitochondrial antioxidant enzymes (A) peroxiredoxin III (Prx-III), 
(B) its oxidized form Prx-SO3, and (C) manganese superoxide dismutase (MnSOD) in heart samples 
of old rats treated with placebo (n = 8) or enalapril (n = 8). Bars represent mean values (± standard 
error of the mean) in the two experimental groups. Values are expressed in arbitrary units. 
Representative blots are shown. * p = 0.0140 vs. placebo; § p = 0.0029 vs. placebo; # p = 0.0450 vs. 
placebo. 
 
Figure 2. Levels of protein-bound carbonyls in heart samples of old rats treated with placebo (n = 8) 
or enalapril (n = 8). Bars represent mean values (± standard error of the mean) in the two 
experimental groups. Values are expressed in arbitrary units. * p = 0.0457 vs. placebo. 
Since increased mitochondrial biogenesis does not always translate into a gain of function [32], 
we determined the content of mtDNA and quantified the abundance of mtDNA4834 deletion and 
mtDNA oxidative damage in the two rat groups. Greater mtDNA content was detected in 
enalapril-treated rats compared with controls (p = 0.001; Figure 3A), together with decreased levels 
of deleted molecules in the same rat group (p = 0.0173; Figure 3B), suggesting that enalapril 
administration might protect against mtDNA damage through increased mtDNA replication. 
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Figure 3. Determination of (A) mtDNA content and (B) mtDNA4834 deletion abundance in heart samples 
of old rats treated with placebo (n = 8) or enalapril (n = 8). Bars represent mean values (± standard error of 
the mean) in the two experimental groups. Values are expressed in arbitrary units. * p = 0.001 vs. 
placebo; § p = 0.0173 vs. placebo. 
The determination of mtDNA oxidative damage provided insightful observations. We focused 
our analysis on short mtDNA sequences including functional regions that regulate mtDNA 
replication and the generation of the mtDNA4834 deletion. The Cytb and D-Loop regions were 
identified as hotspots for oxidative damage, with lower levels of oxidized mtDNA observed in the 
enalapril group (p = 0.0146 and 0.0354 for Cytb and D-Loop, respectively; Figure 4). 
 
Figure 4. Analysis of oxidative base damage to specific regions of mtDNA in heart samples of old 
rats treated with placebo (n = 8) or enalapril (n = 8). Bars represent mean values (± standard error of 
the mean) in the two experimental groups. Data are presented as the ratio between Fpg-treated and 
non-treated samples and show the fraction of mtDNA free of oxidative damage. Representative blots 
are shown. * p = 0.0146 vs. placebo; § p = 0.0354 vs. placebo. 
3.3. Protein Expression of Selected Mediators of Energy Metabolism, Mitochondrial Biogenesis, Dynamics and 
Autophagy 
We started our analysis with the evaluation of mediators involved in cellular energy 
metabolism. To this aim, we analyzed the expression of the conserved fuel-sensing enzyme AMPK 
and its upstream activator, serine-threonine protein kinase AKT. A trend toward decreased content 
of both mediators in the hearts of enalapril-treated rats was observed (Figure 5); however, only 
AMPK reached the statistical significance (p = 0.0408). 
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Figure 5. Protein expression of the active form of (A) protein kinase B (AKT) and (B) AMP-activated 
protein kinase (AMPK) in heart samples of old rats treated with placebo (n = 8) or enalapril (n = 8). 
Data are shown as the ratio between the phosphorylated (upper bands) and non-phosphorylated 
(lower bands) form of the two proteins. Bars represent mean values (± standard error of the mean) in 
the two experimental groups. Values are expressed in arbitrary units. Representative blots are 
shown. * p = 0.0408 vs. placebo. 
Mitochondrial biogenesis signaling was then analyzed via the determination of the protein 
expression of selected mediators including FoXO3 and its ser253 phosphorylated form (FoXO3-P), 
PGC-1α, and TFAM. CS activity was also measured as a marker of mitochondrial mass. FoXO3 
expression was unvaried between groups (p = 0.6043; Figure 6A). Instead, the content of PGC-1α and 
TFAM was greater in rats receiving enalapril compared with controls (p < 0.0001; Figure 6B,C), 
suggesting upregulation of mitochondrial biogenesis under ACE inhibition. Accordingly, CS activity 
was higher in enalapril-treated rats relative to the placebo group (p = 0.0258; Figure 7). 
 
Figure 6. Protein expression of (A) Forkhead boX O3 (FoXO3), (B) peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC-1α), and (C) mitochondrial transcription factor A (TFAM) 
in heart samples of old rats treated with placebo (n = 8) or enalapril (n = 8). FoXO3 expression is 
shown as the ratio between the phosphorylated (upper bands) and non-phosphorylated form (lower 
bands). Bars represent mean values (± standard error of the mean) relative to the placebo group. 
Values are expressed in arbitrary units. Representative blots are shown. * p < 0.0001 vs. placebo. 
 
Figure 7. Citrate synthase activity in heart samples of old rats treated with placebo (n = 8) or enalapril 
(n = 8). Bars represent mean values (± standard error of the mean) in the two experimental groups. 
Values are expressed in μmol × min−1 × g tissue−1. * p = 0.0258 vs. placebo. 
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The protein expression of Mfn2 and Drp1 was measured to obtain indications on mitochondrial 
dynamics signaling in the two experimental groups. The protein content of Mfn2 was higher in the 
enalapril-treated rats (p = 0.0335; Figure 8A), whilst Drp1 expression did not vary between groups (p 
= 0.5237; Figure 8B). As a consequence, the fusion index, calculated as the ratio between Mfn2 and 
Drp1, was higher in the heart of old rats treated with enalapril (p = 0.0320; Figure 8C). This finding 
suggests a shift of mitochondrial dynamics signaling toward fusion following enalapril 
administration. 
 
Figure 8. Protein expression of (A) mitofusin 2 (Mfn2) and (B) dynamin-related protein (Drp1), and 
(C) the fusion index (Mfn2/Drp1) in heart samples of old rats treated with placebo (n = 8) or enalapril 
(n = 8). Bars represent mean values (± standard error of the mean) in the two experimental groups. 
Values are expressed in arbitrary units. Representative blots are shown. * p = 0.0335 vs. placebo; § p = 
0.0320 vs. placebo. 
Finally, we evaluated the expression of two mediators of autophagy: Beclin 1 and SQSTM1/p62. 
The former is the mammalian ortholog of Atg6/vacuolar protein sorting 30 in yeast. Beclin 1 is 
involved in autophagosome formation, cargo recruitment and autophagosome maturation. 
SQSTM1/p62, a ubiquitin-binding scaffold, is a receptor of autophagy that colocalizes with 
ubiquitinated protein aggregates. Higher protein levels of both Beclin 1 and SQSTM1/p62 were 
found in the enalapril group compared with controls (p = 0.0471 and p = 0.0346, respectively; Figure 
9), suggesting that ACE inhibition might impact the autophagic process. 
 
Figure 9. Protein expression of Beclin 1 and sequestome 1 (SQSTM1)/p62 in heart samples of old rats 
treated with placebo (n = 8) or enalapril (n = 8). Bars represent mean values (± standard error of the 
mean) in the two experimental groups. Values are expressed in arbitrary units. Representative blots 
are shown. * p = 0.0471 p = 0.0346 vs. placebo. 
3.4. Analysis of Mitochondrial Transcription Factor A Binding to Specific Regions of Mitochondrial DNA 
Based on previous findings reporting an age-related modulation of TFAM binding to mtDNA 
in several rat tissues [31], we carried out mIP experiments and analyzed the binding of TFAM to 
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three functionally relevant mtDNA regions by qRT-PCR. Such regions encompassed: (1) the portion 
of the D-loop including the light strand transcription promoter (LSP); (2) the tRNA genes stretch 
enclosing OriL; and (3) a sequence containing the direct repeat 1 (DR1) of the 4.8-kb deletion. 
The D-loop- and the OriL-containing regions were selected because of their role in mtDNA 
replication, involving TFAM binding. The region including DR1 was chosen because of the possible 
involvement of TFAM in the generation of mtDNA deletions [33,34]. The tested sequences were far 
enough from each other (600 bp on average) to rule out the possibility of false positive results 
deriving from the amplification of overlapping sequences physically immunoprecipitated by the 
same TFAM molecule [35]. 
The mean amount of TFAM-bound mtDNA in the D-loop region was more than three-fold 
greater in enalapril-treated rats relative to those receiving placebo (p = 0.0452; Figure 10A). A similar 
trend was observed for the OriL and DR1 regions (two-fold and four-fold, respectively) (Figure 
10B,C). However, because of the large within-group variability, the differences did not reach the 
statistical significance (p = 0.4269 and 0.217 for OriL and DR1, respectively; Figure 10B,C). 
 
Figure 10. Determination of TFAM binding to mtDNA regions encompassing D-Loop (A), OriL (B) 
and DR1 (C) in heart samples of old rats treated with placebo (n = 8) or enalapril (n = 8). Bars 
represent mean values (± standard error of the mean) in the two experimental groups. Values are 
expressed in arbitrary units. * p < 0.0452 vs. placebo. 
4. Discussion 
The present study was designed to explore the effects of non-antihypertensive enalapril 
administration started late in life on mitochondrial genomic stability, TFAM binding to mtDNA, and 
MQC signaling in the heart of old rats. We started our experimental plan by measuring mtDNA 
content. To gather insights into the impact of enalapril treatment on mitochondrial mass and 
mtDNA homeostasis, we measured CS activity, the abundance of oxidative lesions and mtDNA4834 
deletion, and the binding of TFAM to specific regions of mtDNA involved in transcription and 
deletion generation. Finally, we explored the effect of enalapril administration on MQC signaling by 
estimating the expression of antioxidant enzymes and selected mediators of mitochondrial 
biogenesis, dynamics, and autophagy. 
Rats treated with enalapril showed a reduced heart weight either absolute or adjusted by BW 
(Table 3), indicative of mitigation of age-related cardiac hypertrophy. A previous study conducted 
by our group using a similar experimental model showed that enalapril administration did not affect 
locomotor activity at any time during the three months of treatment relative to placebo [20]. This 
rules out the possibility that the reduction of the heart weight in enalapril-treated rats may be 
attributed to decreased activity levels. Higher mtDNA copy number was found in the heart of rats 
treated with enalapril (Figure 3A). Even though this adaptation could seem beneficial, it might be 
detrimental if the proportion of damaged molecules is not reduced. Indeed, deleted mtDNA can 
accumulate by virtue of a replicative advantage over wild type molecules [36]. In our experimental 
model, the administration of enalapril was associated with a lower abundance of mtDNA4834 deletion 
(Figure 3B) and a reduced severity of oxidative lesions to functional regions of mtDNA (Cytb and 
D-Loop) (Figure 4). Collectively, these findings support a protective effect of enalapril with regard to 
mitochondrial genome stability in the aged heart. 
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As a further indication of increased mitochondrial mass under ACE inhibition, we determined 
higher CS activity in enalapril-treated rats (Figure 7). This adaptation was likely sustained by 
stimulation of mitochondriogenesis via upregulation of PGC-1α and TFAM (Figure 6B,C) [37]. 
PGC-1α is a transcriptional coactivator that stimulates mitochondrial proliferation in states of 
increased energy demand. The latter is sensed as a higher AMP/ATP ratio by AMPK, an upstream 
regulator of PGC-1α that is activated by phosphorylation [38]. However, different from PGC-1α, 
AMPK activation was blunted by enalapril (Figure 5B). A similar pattern was also determined for 
AKT (Figure 5A). These counterintuitive findings might be explained by the reduced oxidative 
burden detected in the heart of enalapril-treated rats (Figures 2 and 4). Indeed, the activation of both 
AMPK and AKT is promoted by oxidative stress [39,40]. This hypothesis is in line with our previous 
observation of lower hydrogen peroxide generation by subsarcolemmal mitochondria in skeletal 
muscle of old rats treated with enalapril [21]. The upregulation of the expression of the 
mitochondrial detoxifying enzymes PrxIII and MnSOD (Figure 1A,C) lends further support to the 
cardioprotective effects of enalapril via mitigation of oxidative stress. Notably, the expression of 
PrxIII and MnSOD in the heart is induced by PGC-1α [41], therefore establishing a virtuous circle 
involving stimulation of mitochondrial biogenesis and ROS scavenging systems. 
The signaling cascade of PGC-1α proceeds through the activation of nuclear respiratory factors 
that promote the expression of a set of nuclear-encoded mitochondrial proteins [37]. Among these, 
TFAM, a histone-like protein involved in mtDNA replication and transcription, is thought to 
regulate mitochondriogenesis via binding to mtDNA [37]. This hypothesis is supported by the 
finding of increased binding of TFAM to regions that control mtDNA replication (Figure 10A–C). 
Interestingly, in the same regions, levels of oxidized mtDNA were lower in enalapril-treated rats 
compared with controls (Figure 4). Since TFAM binds more avidly to oxidized bases, thereby 
possibly hindering mtDNA repair and replication [19], the reduction in mtDNA oxidation promoted 
by enalapril provides an additional explanation to the upregulation of mitochondrial biogenesis 
under ACE inhibition. 
Further adaptations induced by enalapril involved mitochondrial dynamics signaling. Indeed, 
enalapril-treated rats showed increased protein expression of the fusion protein Mfn2 (Figure 8A), 
whereas Drp1 protein content was unaffected by the treatment (Figure 8B). The consequent increase 
in the fusion index (Figure 8C) suggests that enalapril might promote a shift of mitochondrial 
dynamics towards fusion. It has been hypothesized that this adaptation could serve as a mechanism 
whereby the functionality of damaged mitochondria can be complemented and possibly restored by 
their fusion with neighboring intact organelles [42]. This might be achieved through the dilution of 
mtDNA damage along the network [43]. In support to this idea, disruption of mitochondrial fusion 
via Mfn ablation was found to increase mitochondrial dysfunction and lethality in mtDNA-mutator 
mice [44]. Furthermore, while inhibiting mitochondrial fusion impairs myocardial contractility 
[45–47], the inhibition of mitochondrial fission is cardioprotective against ischemia/reperfusion 
injury in murine models [48]. This is achieved through the formation of elongated mitochondria 
under AKT signaling [49]. 
However, sustained upregulation of mitochondrial fusion may also have drawbacks such as 
inhibition of autophagy. Indeed, damaged mitochondria within the network may be hard to single 
out by fission, thereby hindering their autophagic disposal [50]. In this scenario, while the increased 
expression of Beclin 1 in rats treated with enalapril (Figure 9A) might suggest an induction of 
autophagy, the greater SQSTM1/p62 content found in the same rat group (Figure 9B) may be 
indicate of defective autolysosome clearance. However, our results offer an alternative explanation 
for which upregulation of Beclin 1 and SQSTM1/p62 might reflect greater ongoing autophagy at the 
time of tissue collection. The actual meaning of the pattern of expression of the two autophagy 
mediators cannot be discerned through our experimental design and warrants further investigation. 
Albeit reporting novel findings, our study presents some limitations that deserve being 
acknowledged. All of our biochemical assessments were conducted at a single time-point. Hence, no 
information on the time course of the pathways under investigation could be provided. The amount 
of cardiac tissue available was insufficient for measuring the expression and activity of other 
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relevant mediators of MQC (e.g., microtubule-associated protein 1 light chain 3 beta (LC3B)), ROS 
production, and mtDNA repair enzymes. This, together with the lack of tissue imaging analysis 
investigating the extent of tissue fibrosis and cardiac functional assessment, does not allow for 
drawing definitive conclusions on the nature and extent of adaptations elicited by enalapril. 
However, our experimental plan allowed for interrogating a fairly comprehensive range of 
biochemical events and signaling pathways relevant to cardiac aging. The present data may 
therefore pave the way for future studies aimed at dissecting individual adaptations elicited by 
ACE-inhibitors that might be targeted to achieve better cardiac health in advanced age. 
5. Conclusions 
Findings from the present study indicate that late-life enalapril administration at a 
non-antihypertensive dose attenuates age-associated cardiac hypertrophy and oxidative 
stress-related molecular damage (i.e., mtDNA oxidation, mtDNA4834 deletion, and protein 
carbonylation), while upregulating mitochondrial enzymatic antioxidant defenses. The binding of 
mitochondrial transcription factor A to mtDNA regions involved in replication and deletion 
generation was greater in rats treated with enalapril. The same rat group showed increased indices 
of mitochondrial mass, upregulation of mitochondrial biogenesis signaling, and enhanced 
mitochondrial fusion signaling. Finally, treatment with enalapril was associated with an increased 
protein content of Beclin 1 and SQSTM1/p62. 
Given the wide range of adaptations elicited by enalapril and their potential relevance to 
cardioprotection, further research is warranted to finely dissect the biochemical pathways 
modulated by ACE inhibitors and to establish if these drugs may be used to preserve cardiac health 
into late life. 
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